Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ypsomed Holding AGXSWX:YPSN -0.10%92 EV-to-EBITDA is 16.43 as of Jul. 30, 2026, which is 39% below its 10-year median of 26.81. GuruFocus rates XSWX:YPSN with a GF Score™ of 92/100 and a GF Value™ of CHF396.03 (Fairly Valued). The stock has 6 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Ypsomed Holding AG ranks worse than 57.25% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ypsomed Holding AG's enterprise value is CHF5,362.2 Mil.
Ypsomed Holding AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF326.4 Mil. Therefore, Ypsomed Holding AG's EV-to-EBITDA for today is 16.43.
The historical rank and industry rank for Ypsomed Holding AG's EV-to-EBITDA or its related term are showing as below:
XSWX:YPSN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.09 Med: 26.81 Max: 39.83
Current: 16.43
During the past 13 years, the highest EV-to-EBITDA of Ypsomed Holding AG was 39.83. The lowest was 12.09. And the median was 26.81.
XSWX:YPSN's EV-to-EBITDA is ranked worse than 57.25% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.265
vs XSWX:YPSN: 16.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Ypsomed Holding AG (XSWX:YPSN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ypsomed Holding AG's PE Ratio (TTM) for today is calculated as:
Ypsomed Holding AG's share price for today is CHF390.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ypsomed Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF16.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ypsomed Holding AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:YPSN vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ypsomed Holding AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ypsomed Holding AG's EV-to-EBITDA falls into.
Ypsomed Holding AG's current Enterprise Value is CHF5,362.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ypsomed Holding AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF326.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ypsomed Holding AG (XSWX:YPSN) has a EV-to-EBITDA of 16.43 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ypsomed Holding AG. This is 39% below median its historical median of 26.81. Over the past decade, Ypsomed Holding AG's EV-to-EBITDA has ranged from 12.09 to 39.83. According to the industry distribution chart, Ypsomed Holding AG ranks #292 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 57.3%.
Is Ypsomed Holding AG's EV-to-EBITDA too high?
Ypsomed Holding AG's current EV-to-EBITDA of 16.43 is 39% below median its 10-year median of 26.81. Over the past 10 years, this metric has ranged from a low of 12.09 to a high of 39.83. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.27. Ypsomed Holding AG's value of 16.43 is 15.2% above this industry median. Based on the distribution chart, Ypsomed Holding AG ranks #292 out of 510 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ypsomed Holding AG has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ypsomed Holding AG ranks #292 out of 510 companies for EV-to-EBITDA. This places Ypsomed Holding AG in the lower half of its industry. The industry median EV-to-EBITDA is 14.27. Ypsomed Holding AG's value of 16.43 is 15.2% above this benchmark. Historically, Ypsomed Holding AG's own EV-to-EBITDA has ranged from 12.09 to 39.83 over the past decade. While the company's 10-year median is 26.81 vs. the industry median of 14.27, Ypsomed Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.27, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ypsomed Holding AG's current EV-to-EBITDA of 16.43 is 15.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ypsomed Holding AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current EV-to-EBITDA is 16.43, which is 39% below median its own 10-year median of 26.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Fairly Valued. The stock's GF Value™ is CHF396.03, compared to a current price of CHF390.20 — trading 1.5% below its estimated fair value. The current EV-to-EBITDA is 16.43, which is 39% below median its 10-year median of 26.81 and 15.2% above the Medical Devices & Instruments industry median of 14.27. Ypsomed Holding AG's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current EV-to-EBITDA is 16.43 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued.
The current stock price of CHF390.20 is trading 1.5% below its estimated GF Value™ of CHF396.03.
GuruFocus considers Ypsomed Holding AG to be Fairly Valued.
Key valuation signals for XSWX:YPSN:
EV-to-EBITDA: 16.43 (39% below median its 10-year median of 26.81)
GF Value™: CHF396.03 vs. price of CHF390.20 (1.5% below fair value)
Industry Position: 15.2% above the Medical Devices & Instruments median (#292 of 510)
No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
92GF Score
Get the complete analysis for XSWX:YPSN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:YPSN has been successfully added to your 
